7.31
+0.07(+0.97%)
Currency In USD
| Previous Close | 7.24 |
| Open | 7.21 |
| Day High | 7.37 |
| Day Low | 7.17 |
| 52-Week High | 11.31 |
| 52-Week Low | 6 |
| Volume | 5M |
| Average Volume | 4.21M |
| Market Cap | 1.53B |
| PE | -40.61 |
| EPS | -0.18 |
| Moving Average 50 Days | 7.64 |
| Moving Average 200 Days | 8.44 |
| Change | 0.07 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $813.13 as of October 30, 2025 at a share price of $7.31. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $1,913.61 as of October 30, 2025 at a share price of $7.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
GlobeNewswire Inc.
Oct 23, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma &
BioCryst to Report Third Quarter 2025 Financial Results on November 3
GlobeNewswire Inc.
Oct 20, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management wil
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE portfolio over the next decade – – BioCryst expects